BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-02
141 industry Phase 2/3 trial readout(s) and 32 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-02 | P3 | BioCardia, Inc. BCDA | NCT02438306 CardiAMP™ Cell Therapy for Heart Failure Trial | Heart Failure, Systolic | completed | 125 |
| 2025-02 est. | P2 | Rocket Pharmaceuticals Inc. RCKT | NCT04069533 Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A | Fanconi Anemia Complementation Group A | unknown | 7 |
| 2025-02 est. | P2 | Imbria Pharmaceuticals, Inc. | NCT04306237 A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina | Refractory Angina | withdrawn | |
| 2025-02 est. | P2 | EMS | NCT04666701 Efficacy and Safety of Escócia Association in the Treatment of Acute Pain | Acute Pain | withdrawn | |
| 2025-02 est. | P1/P2 | NGM Biopharmaceuticals, Inc | NCT04913337 Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | Mesothelioma; Glioblastoma; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Melanoma; Pancreatic D | unknown | 179 |
| 2025-02 est. | P1/P2 | Nimbus Saturn, Inc. | NCT05128487 A Study of NDI 1150-101 in Patients With Solid Tumors | Solid Tumor; Renal Cell Carcinoma (Kidney Cancer); Gastric and Gastroesophageal Junction (GEJ) Adeno | active not recruiting | 106 |
| 2025-02 est. | P3 | Reviva Pharmaceuticals RVPH | NCT05184335 Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia | Schizophrenia | recruiting | 690 |
| 2025-02 est. | P2 | Beijing Konruns Pharmaceutical Co., Ltd. | NCT05683886 A Study of KC1036 in Patients with Advanced Thymic Tumors | Thymic Tumors | unknown | 30 |
| 2025-02 est. | P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05686629 An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia | Novel COVID-19-Infected Pneumonia | unknown | 120 |
| 2025-02 est. | P1/P2 | Immunophotonics, Inc. | NCT05688280 Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS | Metastatic Solid Tumor; Colon Cancer; Nonsmall Cell Lung Cancer; Soft Tissue Sarcoma | active not recruiting | 42 |
| 2025-02 est. | P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05688839 A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia | Novel COVID-19-Infected Pneumonia | unknown | 60 |
| 2025-02 est. | P1/P2 | Cantex Pharmaceuticals | NCT05766748 Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | unknown | 30 |
| 2025-02 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05998941 A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Can | Cervical Cancer | withdrawn | |
| 2025-02 est. | P2 | Rivus Pharmaceuticals, Inc. | NCT06104358 Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 D | Diabete Type 2; Obesity | withdrawn | |
| 2025-02 est. | P3 | Addpharma Inc. | NCT06348576 Phase III Study to Evaluate the Efficacy and Safety of AD-209 | Hypertension,Essential | unknown | 280 |
| 2025-02-01 est. | P1/P2 | Stem Cell Medicine Ltd. STEM | NCT03696485 Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS | Secondary Progressive Multiple Sclerosis (SPMS) | withdrawn | |
| 2025-02-01 est. | P2 | Biozeus Biopharmaceutical S.A. | NCT06116045 Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder | Female Sexual Arousal Disorder; Female Sexual Dysfunction | unknown | 30 |
| 2025-02-01 | P1/P2 | Vanarix SA | NCT06897111 Implantation of Cartilage Mini-grafts Made From Donor Cells to Treat Chondral Lesions of the Knee | Cartilage Repair | completed | 10 |
| 2025-02-02 | P2/P3 | Janssen Research & Development, LLC | NCT04119050 Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia | Warm Autoimmune Hemolytic Anemia | active not recruiting | 118 |
| 2025-02-03 | P2 | Lytix Biopharma AS | NCT04796194 Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma | Advanced Melanoma | completed | 23 |
| 2025-02-03 | P2 | AbbVie ABBV | NCT05216250 Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor | Upper Limb Essential Tremor (UL ET) | completed | 174 |
| 2025-02-03 | P3 | Incyte Corporation INCY | NCT05620823 A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | completed | 608 |
| 2025-02-03 | P3 | RDC Clinical Pty Ltd | NCT05950841 Safety and Effectiveness of IHAT in Iron Deficient Pre-menopausal Woman | Iron-deficiency | completed | 180 |
| 2025-02-03 | P2/P3 | AbbVie ABBV | NCT06018987 A Study to Assess Adverse Events and Effectiveness of HAC 20L Injections in Adult Participants for the Treatment of Nasolabial Folds | Nasolabial Folds | completed | 61 |
| 2025-02-03 | P2 | argenx ARGX | NCT06203457 Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | completed | 24 |
| 2025-02-03 | P3 | Pfizer PFE | NCT06593587 A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea | Respiratory Syncytial Virus | completed | 378 |
| 2025-02-04 | P2 | Janssen Research & Development, LLC | NCT04919512 A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder | Urinary Bladder Neoplasms | completed | 163 |
| 2025-02-04 | P3 | Neurocrine Biosciences NBIX | NCT05110157 Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia | Schizophrenia | completed | 442 |
| 2025-02-04 | P2/P3 | Novavax NVAX | NCT06485752 Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine | COVID-19 | withdrawn | |
| 2025-02-05 | P2 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | NCT05001269 Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function | Primary Hyperoxaluria; Primary Hyperoxaluria Type 1; Primary Hyperoxaluria Type 2; Primary Hyperoxal | completed | 27 |
| 2025-02-05 | P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT05046314 A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma | Sarcoma, Ewing | completed | 15 |
| 2025-02-05 | P2/P3 | Camurus AB | NCT05281328 A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | Polycystic Liver Disease | active not recruiting | 71 |
| 2025-02-05 | P1/P2 | Barinthus Biotherapeutics | NCT05617040 Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer | Prostate Cancer | terminated | 22 |
| 2025-02-05 | P2 | Novartis Pharmaceuticals NVS | NCT05885555 A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies | Primary Immune Thrombocytopenia (ITP) | active not recruiting | 41 |
| 2025-02-05 | P3 | UCB Biopharma SRL | NCT06011733 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis | Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis | completed | 133 |
| 2025-02-05 | P1/P2 | Genmab GMAB | NCT06018129 A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | Classical Hodgkin Lymphoma; Non-Hodgkin Lymphoma | terminated | 9 |
| 2025-02-05 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06036927 A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps | Chronic Sinusitis; Nasal Polyps | completed | 80 |
| 2025-02-05 | P1/P2 | Pfizer PFE | NCT06436703 A Study About Modified RNA Vaccines Against Influenza in Healthy Adults | Influenza, Human | completed | 1202 |
| 2025-02-05 | P2 | Palatin Technologies, Inc PTN | NCT06565611 A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | Obesity | active not recruiting | 108 |
| 2025-02-06 | P1/P2 | BeiGene | NCT03744468 Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors | Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in; | completed | 147 |
| 2025-02-06 | P2 | Noema Pharma AG | NCT05059327 Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC | Tuberous Sclerosis Complex | completed | 61 |
| 2025-02-06 | P2 | Sanofi SNY | NCT06118099 Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis | terminated | 90 |
| 2025-02-06 | P1/P2 | Innostellar Biotherapeutics Co.,Ltd | NCT06212297 Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy | Inherited Retinal Dystrophy | active not recruiting | 9 |
| 2025-02-06 | P2 | BioAge Labs, Inc. BIOA | NCT06515418 Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over | Obesity | terminated | 204 |
| 2025-02-06 | P3 | Alcon Research ALC | NCT06660290 A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes | Dry Eye Disease | completed | 55 |
| 2025-02-07 | P2 | Hoffmann-La Roche | NCT03032172 A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy | Spinal Muscular Atrophy | completed | 174 |
| 2025-02-07 | P2 | Novartis Pharmaceuticals NVS | NCT05358717 A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) | Huntington Disease | completed | 159 |
| 2025-02-07 | P2 | ACELYRIN Inc. | NCT05384249 Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis | Uveitis | terminated | 96 |
| 2025-02-07 | P3 | AstraZeneca AZN | NCT05924880 A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unrese | Biliary Tract Cancers | completed | 116 |
| 2025-02-07 | P3 | Axsome Therapeutics, Inc. AXSM | NCT05972044 A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) | ADHD | completed | 516 |
| 2025-02-10 | P3 | Jiangsu Simcere Pharmaceutical Co., Ltd. | NCT04914598 A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions | Malignant Pleural Effusion | active not recruiting | 290 |
| 2025-02-10 | P2 | Palatin Technologies, Inc PTN | NCT05466890 Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) | Ulcerative Colitis; Ulcerative Colitis Acute; Ulcerative; Ulcerative Colitis Flare | active not recruiting | 16 |
| 2025-02-10 est. | P2 | Changzhou Qianhong Bio-pharma Co., Ltd. | NCT06532058 Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia | Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) | unknown | 53 |
| 2025-02-11 | P2 | IntraBio Inc | NCT03759678 N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T) | Ataxia Telangiectasia | terminated | 17 |
| 2025-02-11 | P3 | Nemysis Ltd | NCT06285799 Safety and Effectiveness of Iron Hydroxide Adipate Tartrate (IHAT) in Iron Deficient Premenopausal Women | Iron-deficiency | completed | 180 |
| 2025-02-12 | P2/P3 | Pfizer PFE | NCT01500551 Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis | completed | 302 |
| 2025-02-12 | P3 | UCB Biopharma SRL | NCT04627285 A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Laco | Epilepsy | completed | 48 |
| 2025-02-12 | P2 | AbbVie ABBV | NCT04958031 A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy | Apathy in Dementia | terminated | 41 |
| 2025-02-12 | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT05002270 JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | Advanced Solid Tumor; NSCLC; CRC | completed | 29 |
| 2025-02-12 | P2 | Cothera Bioscience, Inc | NCT05263583 Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | High-grade B-cell Lymphoma; Burkitt Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lym | completed | 14 |
| 2025-02-12 | P1/P2 | Alentis Therapeutics AG | NCT06054477 Study of ALE.C04 in Patients With Head and Neck Cancer | Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma | terminated | 21 |
| 2025-02-12 | P2 | Sanofi SNY | NCT06067425 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia | Osteochondrodysplasia | terminated | 16 |
| 2025-02-13 | P2 | Pfizer PFE | NCT05090566 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | Multiple Myeloma | terminated | 46 |
| 2025-02-13 | P2/P3 | Pfizer PFE | NCT05632354 GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) | Sickle Cell Disease | terminated | 47 |
| 2025-02-13 | P3 | Sinovac Biotech Co., Ltd SVA | NCT05850364 A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine | Poliomyelitis; Polio | completed | 1442 |
| 2025-02-13 | P3 | Nanjing Zenshine Pharmaceuticals | NCT06099873 Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents With Influenza | Respiratory Viral Infection | completed | 361 |
| 2025-02-13 | P2 | Shanghai Huaota Biopharmaceutical Co., Ltd. | NCT06231381 Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP) | Generalized Pustular Psoriasis (GPP) | recruiting | 33 |
| 2025-02-14 | P1/P2 | Eli Lilly and Company LLY | NCT03157128 A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | Non-Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Any Solid Tumor | active not recruiting | 857 |
| 2025-02-14 | P2/P3 | ACADIA Pharmaceuticals Inc. ACAD | NCT05555615 Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder | Irritability Associated With Autism Spectrum Disorder | terminated | 209 |
| 2025-02-14 | P2 | Vigil Neuroscience, Inc. | NCT05677659 A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia | ALSP | terminated | 20 |
| 2025-02-14 | P3 | Merck Sharp & Dohme LLC MRK | NCT06450366 A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic A | Hypercholesterolemia | completed | 301 |
| 2025-02-14 | P1/P2 | Biomind Labs Inc. | NCT06816667 Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety | Healthy Volunteers | completed | 40 |
| 2025-02-15 | P1/P2 | ImmunityBio, Inc. IBRX | NCT05304936 HCW9218 for Advanced Pancreatic Cancer | Advanced Pancreatic Carcinoma | completed | 21 |
| 2025-02-15 est. | P2 | Ethos Research & Development | NCT06247813 Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain | Chronic Pain | unknown | 75 |
| 2025-02-15 | P1/P2 | Biomind Labs Inc. | NCT06812221 Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI | Mild Cognitive Impairment; Anxiety State; Depression Anxiety Disorder | completed | 20 |
| 2025-02-17 | P3 | Hoffmann-La Roche | NCT05171647 A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxali | Non-Hodgkin Lymphoma | active not recruiting | 208 |
| 2025-02-17 | P2 | Novo Nordisk A/S NVO | NCT05442047 A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloid | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | completed | 105 |
| 2025-02-17 | P3 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | NCT05997576 A Study of TG103 Injection in Non-diabetic Overweight or Obesity | Overweight or Obesity | completed | 675 |
| 2025-02-17 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06035393 A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | terminated | 82 |
| 2025-02-17 | P3 | Axsome Therapeutics, Inc. AXSM | NCT06736509 An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation, Psychomot | terminated | 139 |
| 2025-02-18 | P2 | AstraZeneca AZN | NCT04564027 A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer | Advanced Solid Tumours | completed | 54 |
| 2025-02-18 | P3 | Curium US LLC | NCT06235099 Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer | Prostate Cancer; Prostate Adenocarcinoma; Biochemical Recurrence of Malignant Neoplasm of Prostate | completed | 235 |
| 2025-02-18 | P3 | Chiesi Farmaceutici S.p.A. | NCT06264674 Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). | Asthma | completed | 827 |
| 2025-02-18 | P3 | Espad Pharmed | NCT06946160 A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Corre | Glabellar Lines; Glabellar Frown Lines | completed | 146 |
| 2025-02-19 | P1/P2 | Bristol-Myers Squibb BMY | NCT03459222 An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | Advanced Cancer | completed | 229 |
| 2025-02-19 | P1/P2 | Transcend Therapeutics | NCT05741710 A Study to Assess the Use of Methylone in the Treatment of PTSD | Post Traumatic Stress Disorder | completed | 79 |
| 2025-02-19 | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06170190 A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours | Locally Advanced Unresectable or Metastatic Solid Tumors | completed | 19 |
| 2025-02-19 | P3 | Akeso | NCT06378697 A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis | Ankylosing Spondylitis | completed | 510 |
| 2025-02-19 | P3 | CanSino Biologics Inc. | NCT06700148 A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds | Meningococcal Meningitis | completed | 840 |
| 2025-02-20 | P3 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | NCT07739368 Safety and Efficacy Study of Ferric Maltol To Treat Iron Deficiency Anaemia in Chinese Patients With Inflammatory Bowel Disease | Iron Deficiency Anaemia | completed | 122 |
| 2025-02-21 | P3 | Vanda Pharmaceuticals VNDA | NCT04028492 Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis | Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis | completed | 979 |
| 2025-02-21 | P3 | Protagonist Therapeutics, Inc. PTGX | NCT05210790 A Study of Rusfertide in Adults With Polycythemia Vera (PV) | Polycythemia Vera | active not recruiting | 293 |
| 2025-02-21 | P3 | Beijing Mabworks Biotech Co., Ltd. | NCT05314010 A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) | Neuromyelitis Optica Spectrum Disorder | active not recruiting | 102 |
| 2025-02-21 est. | P3 | Qilu Pharmaceutical (Hainan) Co., Ltd. | NCT06446310 Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus | Uremic Pruritus | unknown | 194 |
| 2025-02-22 | P2 | Sanotize Research and Development corp. | NCT06264141 Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis | Recurrent Acute Rhinosinusitis | completed | 162 |
| 2025-02-24 | P2 | Amgen AMGN | NCT04781543 A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis | Diffuse Cutaneous Systemic Sclerosis; Sclerosis, Systemic | terminated | 301 |
| 2025-02-24 | P2 | Genentech, Inc. | NCT05037929 A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | completed | 1334 |
| 2025-02-24 | P2 | Amgen AMGN | NCT05626751 An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) | Diffuse Cutaneous Systemic Sclerosis; Sclerosis, Systemic | terminated | 174 |
| 2025-02-24 | P1/P2 | Akeso | NCT05636267 Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients | NSCLC | terminated | 59 |
| 2025-02-24 | P2 | Novartis Pharmaceuticals NVS | NCT05816395 Safety and Efficacy of RHH646 for Knee Osteoarthritis | Osteoarthritis, Knee | completed | 82 |
| 2025-02-24 | P2 | Recursion Pharmaceuticals Inc. RXRX | NCT06005974 A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation | AXIN1 Gene Mutation; APC Gene Mutation; Solid Tumor | terminated | 18 |
| 2025-02-24 | P2 | AbbVie ABBV | NCT06151535 A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants | Skin Quality Deficit | completed | 30 |
| 2025-02-25 | P2 | Astellas Pharma Global Development, Inc. | NCT04225117 A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Locally Advanced or Metastatic Malignant Solid Tumors | active not recruiting | 329 |
| 2025-02-25 | P3 | Sumitomo Pharma Switzerland GmbH | NCT04756037 Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy | Contraception | completed | 1164 |
| 2025-02-25 est. | P2 | Amgen AMGN | NCT05323617 Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy | Severe Aplastic Anemia (SAA) | withdrawn | |
| 2025-02-25 | P2 | Veradermics, Inc. MANE | NCT05799157 Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | Verruca Vulgaris; Warts; Common Wart | completed | 153 |
| 2025-02-26 | P3 | GlaxoSmithKline | NCT04475939 Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastati | Lung Cancer, Non-Small Cell | completed | 666 |
| 2025-02-26 | P3 | AstraZeneca AZN | NCT05202262 A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Con | Asthma | completed | 645 |
| 2025-02-26 | P3 | Boehringer Ingelheim | NCT05211947 A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study | Schizophrenia | terminated | 1356 |
| 2025-02-26 | P2 | Alterity Therapeutics ATHE | NCT05864365 A Biomarker Study of ATH434 in Participants With MSA | Multiple System Atrophy | completed | 10 |
| 2025-02-26 | P3 | Merck Sharp & Dohme LLC MRK | NCT06177912 A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) | Pneumococcal Infection | completed | 882 |
| 2025-02-26 | P2 | Boehringer Ingelheim | NCT06280235 A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine | Depressive Disorder, Major | completed | 243 |
| 2025-02-26 | P3 | AbbVie ABBV | NCT06308198 A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines | Glabellar Lines | completed | 161 |
| 2025-02-26 | P3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT07047196 Evaluating the Efficacy and Safety of Intra-articular Injection of HS-20116 in Patients With Knee Osteoarthritis | Knee Osteoarthritis | completed | 192 |
| 2025-02-27 | P1/P2 | Hoffmann-La Roche | NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | Pancreatic Adenocarcinoma | completed | 341 |
| 2025-02-27 | P3 | Regeneron Pharmaceuticals REGN | NCT03409614 Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | Non-small Cell Lung Cancer | completed | 789 |
| 2025-02-27 | P2 | Transposon Therapeutics, Inc. | NCT05613868 TPN-101 in Aicardi-Goutières Syndrome (AGS) | Aicardi-Goutières Syndrome (AGS) | terminated | 4 |
| 2025-02-27 | P3 | Amgen AMGN | NCT05704738 A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) | Atopic Dermatitis | completed | 532 |
| 2025-02-27 | P2 | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | NCT06148649 Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes | completed | 234 |
| 2025-02-27 | P2 | Mineralys Therapeutics Inc. MLYS | NCT06150924 Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease ( | Chronic Kidney Disease | completed | 60 |
| 2025-02-27 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06242652 A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS) | Ankylosing Spondylitis | unknown | 250 |
| 2025-02-27 | P3 | Aldeyra Therapeutics, Inc. ALDX | NCT06493604 A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease | Dry Eye Disease | completed | 116 |
| 2025-02-27 | P2 | Biomed Industries, Inc. | NCT06564753 Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition | Weight Loss; Obesity; Body Weight; Body Weight Changes | completed | 126 |
| 2025-02-27 | P2 | Rose Pharma Inc | NCT06621017 Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects | Obesity; Overweight | completed | 40 |
| 2025-02-28 | P3 | Merck Sharp & Dohme LLC MRK | NCT03903562 Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024) | Papillomavirus Infections | completed | 1990 |
| 2025-02-28 | P3 | Maggie's Pearl, LLC | NCT04925960 Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG | Pmm2-CDG; Phosphomannomutase 2 Deficiency; Phosphomannomutase 2 Congenital Disorder of Glycosylation | terminated | 42 |
| 2025-02-28 est. | P1/P2 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT04954001 Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Typ | Neurofibromatosis 1; Plexiform Neurofibroma; NF1 | unknown | 160 |
| 2025-02-28 | P3 | Pharmbio Korea Co., Ltd. | NCT05509868 Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea | Acute Pain | completed | 182 |
| 2025-02-28 est. | P1/P2 | RedCloud Bio RCT | NCT05519293 Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | Non-small Cell Lung Cancer | unknown | 76 |
| 2025-02-28 est. | P1/P2 | RedCloud Bio RCT | NCT05552781 H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC | Non-small Cell Lung Cancer | unknown | 76 |
| 2025-02-28 | P3 | Cytokinetics CYTK | NCT05767346 Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM | Obstructive Hypertrophic Cardiomyopathy (oHCM) | completed | 175 |
| 2025-02-28 est. | P3 | Sichuan Jishengtang Pharmaceutical Co., Ltd. | NCT05772104 Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder | Generalized Anxiety Disorder | recruiting | 495 |
| 2025-02-28 | P3 | Akeso | NCT05840016 AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer | Advanced Squamous Non Small Cell Lung Cancer | active not recruiting | 532 |
| 2025-02-28 | P2 | Incyte Corporation INCY | NCT05936567 Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria | Urticaria; Chronic Spontaneous Urticaria; Chronic Idiopathic Urticaria; Hives; Angioedema; Pruritis | completed | 136 |
| 2025-02-28 est. | P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT05937867 A Phase II Study of HS-10353 in Participants With Postpartum Depression | Postpartum Depression | unknown | 96 |
| 2025-02-28 est. | P3 | Daewoong Pharmaceutical Co. LTD. | NCT06025409 Evaluate the Efficacy and Safety of DWJ108J | Central Precocious Puberty | unknown | 79 |
| 2025-02-28 | P3 | Amgen AMGN | NCT06122649 A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) | Plaque Psoriasis | completed | 203 |
| 2025-02-28 est. | P1/P2 | Shenzhen TargetRx Co., Ltd. | NCT06206174 TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | Hematologic Malignancy; Non Hodgkin Lymphoma; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia, | recruiting | 30 |
| 2025-02-28 | P3 | Abbott ABT | NCT06217393 Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia | Functional Dyspepsia | completed | 564 |
| 2025-02-28 | P2 | Priovant Therapeutics, Inc. | NCT06433999 A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis | Dermatomyositis; Dermatomyositis, Adult Type | completed | 5 |
| 2025-02-28 est. | P1/P2 | Primoris Therapeutics PRIM | NCT06440239 A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s) | Burns; Burn Degree Second | unknown | 40 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.